Supplementary Material for:

Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans

Gissette Reyes-Soffer,* Byoung Moon, Antonio Hernandez-Ono, Marija Dionizovick-Dimanovski, Jhonsua Jimenez, Joseph Obunike, Tiffany Thomas, Colleen Ngai, Nelson Fontanez, Daniel S. Donovan, Wahida Karmally, Stephen Holleran, Rajasekhar Ramakrishnan, Robert S. Mittleman, Henry N. Ginsberg*

*Corresponding author. E-mail: gr2104{at}cumc.columbia.edu (G.R.-S.); hng1{at}cumc.columbia.edu (H.N.G.)

Published 27 January 2016, Sci. Transl. Med. 8, 323ra12 (2016)
DOI: 10.1126/scitranslmed.aad2195

This PDF file includes:

• Methods
• Fig. S1. Study flow diagram.
• Fig. S2. No changes in LDLR, IDOL, or PCSK9 mRNA levels in HepG2 cells after knockdown of APOB.
• Fig. S3. ApoB ASO inhibits hepatic secretion of TG and apoB from mice on either chow or HFD diet.
• Fig. S4. ApoB secretion is increased in Apobec-1 knockout mice on HFD.
• Fig. S5. ApoB siRNA treatment does not affect expression of Ldlr, Idol, or csk9P in mouse livers.
• Fig. S6. Hepatic LDL receptor was not affected by ApoB ASO.
• Fig. S7. Relationship between mipomersen-induced reductions in VLDL apoB PR and baseline VLDL PR.
• Table S1. Participant information.
• Table S2. Effect of mipomersen on apoB lipoprotein particle number by ion mobility analysis.
• Table S3. Effect of mipomersen on apoB lipoprotein size distribution by ion mobility analysis.
• Table S4. Effect of mipomersen on LDL size subfraction particle numbers by ion mobility analysis.
• Table S5. Markers of cholesterol synthesis and absorption.
• Table S6. Hepatic lipase, lipoprotein lipase, FFA, and β-hydroxybutyrate levels.
• Table S7. Individual participant apoB kinetics of VLDL, IDL, LDL, and VLDL TG FCR.
• References (43–49)

[Download PDF]